Balazs Sumegi Selected Research

2- ((2- piperidin- 1- ylethyl)thio)quinazolin- 4(3H)- one

1/2017	Chronic PARP-1 inhibition reduces carotid vessel remodeling and oxidative damage of the dorsal hippocampus in spontaneously hypertensive rats.
7/2014	A quinazoline-derivative compound with PARP inhibitory effect suppresses hypertension-induced vascular alterations in spontaneously hypertensive rats.
1/2014	PARP-inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, Akt-1/GSK-3β and several PKC isoforms.
9/2008	Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure.
7/2006	PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Balazs Sumegi Research Topics

Disease

13	Neoplasms (Cancer) 04/2020 - 03/2002
9	Heart Failure 01/2021 - 07/2006
9	Ischemia 01/2013 - 12/2002
8	Inflammation (Inflammations) 01/2019 - 07/2004
6	Hypertrophy 01/2021 - 07/2006
5	Hypertension (High Blood Pressure) 01/2021 - 01/2013
5	Necrosis 01/2017 - 10/2005
4	Fibrosis (Cirrhosis) 01/2017 - 07/2006
4	Cardiomegaly (Heart Hypertrophy) 01/2017 - 07/2006
3	Disease Progression 01/2021 - 01/2017
3	Neoplasm Metastasis (Metastasis) 01/2020 - 02/2009
3	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2020 - 02/2009
3	Septic Shock (Toxic Shock Syndrome) 02/2009 - 04/2003
3	Infarction (Infarctions) 09/2006 - 12/2003
2	Endotoxemia 01/2021 - 12/2015
2	Shock 01/2021 - 07/2004
2	Sepsis (Septicemia) 01/2021 - 12/2015
2	Melanoma (Melanoma, Malignant) 01/2020 - 01/2019
2	Urinary Bladder Neoplasms (Bladder Cancer) 10/2018 - 01/2017
2	Vascular Remodeling 01/2017 - 07/2014
2	Glioblastoma (Glioblastoma Multiforme) 12/2014 - 01/2013
2	Cardiotoxicity 06/2012 - 01/2005
2	Cardiomyopathies (Cardiomyopathy) 10/2011 - 01/2005
2	Leiomyoma (Uterine Fibroids) 09/2010 - 02/2007
2	Carcinoma (Carcinomatosis) 02/2009 - 03/2003
2	Myocardial Infarction 09/2008 - 07/2006
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2021
1	Systolic Heart Failure 11/2020
1	Hypoxia (Hypoxemia) 01/2019
1	Retinal Diseases 01/2019
1	Pulmonary Arterial Hypertension 01/2018
1	Autosomal Dominant Optic Atrophy (Dominant Optic Atrophy) 01/2018
1	Insulin Resistance 01/2018
1	Glioma (Gliomas) 01/2017
1	Acute Lung Injury 12/2015
1	Lung Injury 12/2015

Drug/Important Bio-Agent (IBA)

19	Poly(ADP-ribose) Polymerase InhibitorsIBA 04/2020 - 04/2003
12	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 04/2020 - 04/2003
11	Phosphotransferases (Kinase)IBA 02/2020 - 07/2004
9	Proteins (Proteins, Gene)FDA Link 01/2018 - 12/2002
7	EnzymesIBA 04/2020 - 04/2003
6	Pharmaceutical PreparationsIBA 01/2021 - 07/2006
6	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021 - 01/2004
5	BGP 15IBA 01/2021 - 03/2002
5	LipopolysaccharidesIBA 01/2021 - 04/2003
5	Amiodarone (Amiodarona)FDA LinkGeneric 01/2020 - 04/2003
5	2- ((2- piperidin- 1- ylethyl)thio)quinazolin- 4(3H)- oneIBA 01/2017 - 07/2006
4	desethylamiodaroneIBA 01/2020 - 11/2003
4	Cytostatic AgentsIBA 01/2019 - 04/2009
4	p38 Mitogen-Activated Protein KinasesIBA 01/2017 - 01/2014
4	Isoproterenol (Isoprenaline)FDA LinkGeneric 01/2017 - 07/2006
3	CollagenIBA 01/2021 - 07/2006
3	ResveratrolIBA 11/2020 - 05/2013
3	Poly (ADP-Ribose) Polymerase-1IBA 01/2019 - 07/2004
3	N- (oxo- 5,6- dihydrophenanthridin- 2- yl)- N,N- dimethylacetamide hydrochlorideIBA 01/2019 - 04/2003
3	EndotoxinsIBA 12/2015 - 04/2003
3	Mitogen-Activated Protein KinasesIBA 12/2014 - 07/2006
3	Transcription Factors (Transcription Factor)IBA 07/2014 - 07/2004
3	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2014 - 10/2011
3	Adenosine Triphosphate (ATP)IBA 06/2012 - 10/2005
3	Phosphates (Orthophosphate)IBA 06/2012 - 12/2002
3	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 05/2012 - 04/2003
3	PolyphenolsIBA 01/2011 - 02/2009
3	Glycogen Synthase Kinase 3 betaIBA 09/2008 - 02/2006
3	NAD (NADH)IBA 02/2006 - 12/2002
3	AntioxidantsIBA 01/2005 - 04/2003
2	Cyclophilins (Cyclophilin)IBA 01/2021 - 12/2015
2	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2021 - 05/2013
2	Temozolomide (Temodar)FDA LinkGeneric 01/2019 - 01/2013
2	Cisplatin (Platino)FDA LinkGeneric 01/2019 - 03/2002
2	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 01/2017 - 12/2002
2	Oxygen (Dioxygen)IBA 01/2017 - 12/2015
2	Protein Isoforms (Isoforms)IBA 08/2016 - 01/2014
2	CytokinesIBA 12/2015 - 01/2014
2	Small Heat-Shock ProteinsIBA 01/2015 - 12/2007
2	NF-kappa B (NF-kB)IBA 07/2014 - 07/2004
2	LipidsIBA 01/2013 - 03/2003
2	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2011 - 01/2005
2	ferulaldehydeIBA 01/2011 - 02/2009
2	Apoptosis Inducing FactorIBA 03/2010 - 11/2003
2	Protein Kinase CIBA 06/2009 - 07/2006
2	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 02/2006 - 07/2004
2	WortmanninIBA 02/2006 - 12/2003
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Therapeutic UsesIBA 04/2020
1	Retinaldehyde (Retinal)IBA 01/2019
1	olaparibIBA 01/2019
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019
1	Hydroxylamine (Hydroxylamine Hydrochloride)IBA 01/2018
1	GTP Phosphohydrolases (GTPases)IBA 01/2018
1	Dynamins (Dynamin)IBA 01/2018
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2017
1	Glucose (Dextrose)FDA LinkGeneric 01/2017
1	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2017
1	Doxycycline (Periostat)FDA LinkGeneric 01/2017
1	NitrogenIBA 12/2015
1	NitritesIBA 06/2015

Therapy/Procedure

14	Therapeutics 11/2020 - 01/2009